

Item 2.02. Results of Operations and Financial Condition

On May 4, 2016, Spark Therapeutics, Inc. (the “Company”) issued a press release announcing unaudited consolidated financial results for the quarter ended March 31, 2016. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by preference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

Exhibit 99.1 Press release issued by Spark Therapeutics, Inc., dated May 4, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPARK
THERAPEUTICS,
INC.

Date: May 4, 2016

By: /s/ Joseph W.
La Barge
Joseph W. La
Barge
General
Counsel

Exhibit Index

Exhibit 99.1 Press release issued by Spark Therapeutics, Inc., dated May 4, 2016.